The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...

New year, new Veeda. The India-based CRO formerly known as Veeda Group has kicked off 2025 with a brand makeover.

Currax Pharmaceuticals is kicking off the new year with a new direct-to-consumer campaign for its weight loss medication ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Academics are calling for governments to act to “safeguard the ind | Academics are calling for governments to act to “safeguard the independence” of patient groups that receive funding from biopharma ...